The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours

L. F. Porrata, A. A. Adjei

Research output: Contribution to journalReview article

26 Scopus citations

Abstract

The theoretical basis of high dose chemotherapy with haematopoietic stem cell support (HDT) for solid tumours is the presumption of a linear, steep dose-response relationship for chemotherapy conditioning agents. We review preclinical pharmacologic studies evaluating steep dose-response relationships for different chemotherapeutic agents, identified through a MED-LINE and CANCER-LIT search of the English medical literature from January 1966 to December 1999. Only BCNU, melphalan, nitrogen mustard, and the combination of thiotepa and cyclophosphamide demonstrated steep dose-response relationships over a wide dose-range. The pharmacologic evidence for the use of other antineoplastic agents for HDT in solid tumours is non-existent. More preclinical studies are needed for a rational development of this therapeutic approach for solid tumours.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalBritish journal of cancer
Volume85
Issue number4
DOIs
StatePublished - Aug 17 2001

Keywords

  • High-dose chemotherapy
  • Preclinical pharmacology
  • Solid tumours

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours'. Together they form a unique fingerprint.

  • Cite this